Ingram Cheung

Ingram Cheung is a Counsel in the firm’s Business Law Department and a member of the Private Equity group in Hong Kong. His practice focuses on advising private equity sponsors, institutional investors, and multinational corporations on cross-border and domestic mergers and acquisitions, divestments, growth capital and pre-IPO investments, joint ventures, and reorganizations, as well as Hong Kong IPOs, takeovers, and equity capital markets transactions.

Ingram’s recent experience includes representation of:

• FountainVest Partners on its investment alongside CPE in SML Group, a global leader in brand identification tags and RFID solutions headquartered in Hong Kong with operations across Greater China, Asia Pacific, EMEA and the Americas
• Tamarind Health, a Templewater portfolio company, on the take private acquisition of TalkMed Group, a Singapore-listed pan-Asian oncology-focused group
• Templewater on the acquisition of Icon Group’s Hong Kong assets
• Templewater on the establishment and financing of a medical specialty clinics group, Tamarind Health
• Biotheus on its sale to BioNTech for $800 million upfront, plus $150 million potential milestones
• Curon on its sale to Merck for $700 million upfront, plus $600 million potential milestones
• OncoC4, Inc. on its Series B financing
• LionRock Capital on its acquisition of Haglöfs AB, a leading outdoor performance brand, from ASICS Corporation
• Softbank Group Corp. as lead investor in its investment in the $280 million Series E financing round of Mapbox, a location platform powering navigation
• The management of ELEVATE on the sale of ELEVATE, an industry leader in ESG and supply chain services globally, by the Elevate management team and EQT to LRQA
• LionRock Capital on the sale of a majority stake in leading shoe manufacturer and retailer Clarks 
  
   

Prior to joining Goodwin, Ingram was a senior associate in the Hong Kong office of Freshfields Bruckhaus Deringer.